Literature DB >> 16470226

Integrated signalling pathways for mast-cell activation.

Alasdair M Gilfillan1, Christine Tkaczyk.   

Abstract

Mast-cell activation mediated by the high-affinity receptor for IgE (FcepsilonRI) is considered to be a key event in the allergic inflammatory response. However, in a physiological setting, other receptors, such as KIT, might also markedly influence the release of mediators by mast cells. Recent studies have provided evidence that FcepsilonRI-dependent degranulation is regulated by two complementary signalling pathways, one of which activates phospholipase Cgamma and the other of which activates phosphatidylinositol 3-kinase, using specific transmembrane and cytosolic adaptor molecules. In this Review, we discuss the evidence for these interacting pathways and describe how the capacity of KIT, and other receptors, to influence FcepsilonRI-dependent mast-cell-mediator release might be a function of the relative abilities of these receptors to activate these alternative pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470226     DOI: 10.1038/nri1782

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  296 in total

Review 1.  Deciphering the structure and function of FcεRI/mast cell axis in the regulation of allergy and anaphylaxis: a functional genomics paradigm.

Authors:  Jayapal Manikandan; Narasimhan Kothandaraman; Manoor Prakash Hande; Peter Natesan Pushparaj
Journal:  Cell Mol Life Sci       Date:  2011-12-07       Impact factor: 9.261

2.  IL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling.

Authors:  Daniel Traum; Patricia Timothee; Jonathan Silver; Stefan Rose-John; Matthias Ernst; David F LaRosa
Journal:  J Leukoc Biol       Date:  2011-12-02       Impact factor: 4.962

Review 3.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

4.  Macelignan inhibits histamine release and inflammatory mediator production in activated rat basophilic leukemia mast cells.

Authors:  Young Sun Han; Myung-Suk Kim; Jae-Kwan Hwang
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

5.  Phosphatidylinositol-3-kinase C2β and TRIM27 function to positively and negatively regulate IgE receptor activation of mast cells.

Authors:  Shekhar Srivastava; Xinjiang Cai; Zhai Li; Yi Sun; Edward Y Skolnik
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 6.  LAB/NTAL/Lat2: a force to be reckoned with in all leukocytes?

Authors:  Selinda J Orr; Daniel W McVicar
Journal:  J Leukoc Biol       Date:  2010-07-19       Impact factor: 4.962

7.  Mast cell function is not altered by Coronin-1A deficiency.

Authors:  Sanja Arandjelovic; Dilki Wickramarachchi; Saskia Hemmers; Sunamita S Leming; Dwight H Kono; Kerri A Mowen
Journal:  J Leukoc Biol       Date:  2010-07-19       Impact factor: 4.962

8.  Kit- and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells.

Authors:  Shoko Iwaki; Jiri Spicka; Christine Tkaczyk; Bettina M Jensen; Yasuko Furumoto; Nicolas Charles; Martina Kovarova; Juan Rivera; Vaclav Horejsi; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Signal       Date:  2007-10-16       Impact factor: 4.315

9.  CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Authors:  Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

10.  Inhibitory effects of methamphetamine on mast cell activation and cytokine/chemokine production stimulated by lipopolysaccharide in C57BL/6J mice.

Authors:  Li Xue; Yan Geng; Ming Li; Yao-Feng Jin; Hui-Xun Ren; Xia Li; Feng Wu; Biao Wang; Wei-Ying Cheng; Teng Chen; Yan-Jiong Chen
Journal:  Exp Ther Med       Date:  2018-02-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.